Test ID CASRZ CASR Gene, Full Gene Analysis, Varies
Useful For
Establishing a diagnosis of familial hypocalciuric hypercalcemia
As part of the workup of some patients with primary hyperparathyroidism
Establishing a diagnosis of neonatal severe primary hyperparathyroidism
Establishing a diagnosis of autosomal dominant hypoparathyroidism
As part of the workup of idiopathic hypoparathyroidism
As part of the workup of patients with Bartter syndrome
Special Instructions
Method Name
Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis
Reporting Name
CASR Gene, Full Gene AnalysisSpecimen Type
VariesShipping Instructions
Specimen preferred to arrive within 96 hours of draw.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send specimen in original tube.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Frozen | |||
Refrigerated |
Reference Values
An interpretive report will be provided
Day(s) and Time(s) Performed
Performed weekly; Varies
Performing Laboratory

CPT Code Information
81405-CASR (calcium-sensing receptor) (eg, hypocalcemia), full gene sequence
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
CASRZ | CASR Gene, Full Gene Analysis | 82534-9 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
37446 | Result Summary | 50397-9 |
37447 | Result | 82939-0 |
37448 | Interpretation | 69047-9 |
37449 | Additional Information | 48767-8 |
37450 | Specimen | 31208-2 |
37451 | Source | 31208-2 |
37452 | Released By | 18771-6 |
NY State Approved
YesTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Calcium Sensing Receptor (CASR) Gene Testing Patient Information (T551) in Special Instructions